Effects of GLP-1 on appetite and weight

Reviews in Endocrine and Metabolic Disorders

Volumn 15, Issue 3, 2014, Pages 181-187

  Shah, Meera ^a   Vella, Adrian ^a  

^a MAYO CLINIC   (United States)

Author keywords

Appetite; Bariatric surgery; Gastric accommodation; Gastric emptying; Satiety

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; PROGLUCAGON;

APPETITE; BODY WEIGHT; BRAIN STEM; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HORMONE ACTION; HUMAN; HYPOTHALAMUS; INTESTINE CELL; NERVE CELL; NONHUMAN; PANCREAS ISLET ALPHA CELL; REVIEW; SATIETY; STOMACH EMPTYING; EATING; METABOLISM; PHYSIOLOGY;

APPETITE; BODY WEIGHT; EATING; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 84906263895     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-014-9289-5     Document Type: Review

References (74)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-39. (Pubitemid 350041474)
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. (Pubitemid 46711096)
3. Dailey MJ et al. Disassociation between preprandial gut peptide release and food-anticipatory activity. Endocrinology. 2012;153:132-42.
4. Vahl TP et al. Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology. 2010;151:569-75.
5. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord. 2001;25 Suppl 5:S42-7. (Pubitemid 34146322)
6. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138:159-66. (Pubitemid 23266831)
7. Hermann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion. 1995;56:117-26.
8. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon- like peptide-1 secretion. Endocrinology. 1999;140(4):1687-94. (Pubitemid 29149238)
9. Balks HJ, Holst JJ, Von Zur MA, Brabant G. Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: Cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab. 1997;82(3):786-90. (Pubitemid 27106588)
10. Theodorakis MJ, Carlson O, Michopoulos S, et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 2006;290:E550-9. (Pubitemid 43671703)
11. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol. 2009;587(1):27-32.
12. Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Oxyntomodulin from distal gut: role in regulation of gastric and pancreatic functions. Dig Dis Sci. 1989;34:1411-9. (Pubitemid 19247399)
13. Tang-Christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med. 2000;6(7):802-7. (Pubitemid 30469430)
14. Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ. Glucagon-like Peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem. 2001;276(24):21489-99.
15. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981-8.
16. Schirra J, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1 (7-36) amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50:341-8. (Pubitemid 34161049)
17. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719-25. (Pubitemid 36733545)
18. Delgado-Aros S, Doe-Young K, Burton DD, Thomforde GM, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G424-31. (Pubitemid 34651657)
19. Ruttimann EB et al. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology. 2009;150:1174-81.
20. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69-72. (Pubitemid 26008136)
21. Barrera JG et al. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci. 2011;31:3904-13.
22. Chaudhri OB, Parkinson JR, Kuo YT, et al. Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. Biochem Biophys Res Commun. 2006;350:298-306. (Pubitemid 44515085)
23. Min DK, Tuor UI, Koopmans HS, Chelikani PK. Changes in differential functional magnetic resonance signals in the rodent brain elicited by mixed-nutrient or protein-enriched meals. Gastroenterology. 2011;141:1832-41.
24. Dailey M.J., Moran T. H. Glucagon-like peptide 1 and appetite. Trends in Endocrinology and Metabolism. 2013; 24 (2).
25. Larsen PJ et al. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 1997;138:4445-55. (Pubitemid 27408493)
26. Seo S. Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats. Endocr J. 2008;55:867-74.
27. Bugarith K et al. Basomedial hypothalamic injections of neuropeptide Y conjugated to saporin selectively disrupt hypothalamic controls of food intake. Endocrinology. 2005;146:1179-91. (Pubitemid 40289307)
28. Blevins JE, Baskin DG. Hypothalamic-brainstem circuits controlling eating. Forum Nutr. 2010;63:133-40.
29. Richards P, Parker HE, Adriaenssens AE, et al. (2013) Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model. Diabetes; Publish Ahead of Print, published online December 2, 2013.
30. Kinzig KP et al. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci. 2002;22:10470-6. (Pubitemid 35416883)
31. Dailey MJ, Moran T. H. Glucagon-like peptide 1 and appetite. Trends in Endocrinology and Metabolism. 2013;24 (2).
32. Kellum JM, Kuemmerle JF, O'Dorisio TM. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990;211:763-70.
33. Laferrère B, Teixeira JMJ. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479-85. (Pubitemid 352008510)
34. le Roux CW, Aylwin SJ, Batterham RL. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243:108-14. (Pubitemid 43054062)
35. Kashyap SR, Bhatt DL, Wolski K. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013;36:2175-82.
36. Gagner M. Sleeve gastrectomy: an ideal choice for T2DM. Nat Rev Endocrinol. 2013;9:623.
37. Habegger KM, Kirchner H, Yi CX, Heppner KM, et al. GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. Diabetes Care. 2013;62(9):3261-7.
38. Shah M, Law JH, Micheletto F, et al. Contribution of endogenous glucagon-like peptide-1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes. 2014;63:1-10.
39. Deane AM, Nguyen NQ, Stevens JE. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab. 2010;95:215-21.
40. Nicolaus M, Brödl J, Linke R, Woerle H-J, Göke B, Schirra J. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying. J Clin Endocrinol Metab. 2011;96:229-36.
41. Wilson-Perez HE, Chambers AP, Ryan KK, Li B, Sandoval DA, et al. Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes. 2013;62(7):2380-5.
42. Nea I. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Rev. 1997;273:G920-7.
43. Aea W. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998;275:G984-92.
44. Aea A. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil. 2010;22:664-e203.
45. Mea T-C. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271:R848-56.
46. Gulpinar MA. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats. Am J Physiol Gastrointest Liver Physiol. 2000;278:924-9.
47. Ayachi SE. Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39). Neurogastroenterol Motil. 2005;17:302-9. (Pubitemid 40476692)
48. Yoder SM. Stimulation of incretin secretion by dietary lipid: is it dose dependent? Am J Physiol Gastrointest Liver Physiol. 2009;297:299-305.
49. Wank U, Schirra J, Arnold R, Goke B, Katschinki M. Effects of GLP-1 on proximal gastric motor and sensory function in human. Gastroenterology. 1998;114:A1190.
50. Delgado-Aros S, Vella A, Camilleri M, et al. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil. 2003;15:435-43. (Pubitemid 36876259)
51. Holst JJ, Toft-Nielsen MB, Orskov C, Nauck M, Willms B. On the effects of glucagon-like peptide-1 on blood glucose regulation in normal and diabetic subjects. Ann N Y Acad Sci. 1996;805:729-36. (Pubitemid 27058086)
52. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a arallel-group study. Lancet. 2002;359:824-30. (Pubitemid 34233752)
53. Vilsboll T, Christensen M, Junker AE FKK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:7771.
54. Buse JB, Henry RR, Han J, Kim DD, MS F, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-35. (Pubitemid 39441462)
55. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-100. (Pubitemid 40616618)
56. Moretto TJ, Milton DR RT, Macconell LA, Okerson T, AM W, Brodows RG. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group study. Clin Ther. 2008;30:1448-60.
57. Astrup A, Rossner S, Van GL, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606-16.
58. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin. 2009;25:65-75.
59. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046-55.
60. Gallwitz B, Bohmer M, Segiet T, et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 2011;34:604-6.
61. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
62. Buse JB, Nauck M, Forst T. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-24.
63. Kelly A, Rudser KD, Nathan BM, Fox CK, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity. JAMA Pediatr. 2013;167(4):355-60.
64. Bunck MC, Diamant M, Eliasson B, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33:1734-7.
65. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163-72.
66. Zoicas F, Droste M, Mayr B, Buchfelder M, Schofl C, et al. GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases. Eur J Endocrinol. 2013;168(5):699-706.
67. Garber A, Henry RR RR, Hale P, CT C, Bode B. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:348-56.
68. Macconell L, Pencek R, Li Y, Maggs D, Porter L. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31-41.
69. Bunck MC, Corner A, Eiasson B, et al. Effects of exenatide on measures of beta-cell function after 3years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2041-7.
70. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of GLP-1 on appetite and body weight: focus on the central nervous system. J Endocrinol. 2013 (Dec 9. [Epub ahead of print]).
71. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595-604.
72. Kral JG. Vagal nerve function in obesity: therapeutic implications. World J Surg. 2009;33:1995-2006.
73. Hoyda TD, Smoth PM, Ferguson AV. Gastrointestinal hormone actions in the central regulation of energy metabolism: potential sensory roles for the circumventricular organs. Int J Obes. 2009;33:S16-21.
74. Thorens B, Larsen P. Gut-derived signaling molecules and vagal afferents in the control of glucose and energy homeostasis. Curr Opin Clin Nutr Metab Care. 2004;7:471-8. (Pubitemid 40340656)